Extended Data Figure 5: Injection of Flt3 ligand-derived dendritic cells into tumours of BrafV600E/Pten−/−/CAT-STA mice is sufficient to overcome the lack of CD103+ dermal dendritic cells.
From: Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
a, Expression level of Ifnb in CD45+CD11c+ sorted dendritic cells from tumours from BrafV600E/Pten−/− (open bars) and BrafV600E/Pten−/−/CAT-STA (filled bars) mice. FC, fold change. b, Expression level of Batf3, Irf8 and Itgae in sorted dendritic cells. Fold change is indicated in each graph (n = 8). c, Mean (± s.e.m.) tumour weight of BrafV600E/Pten−/−/CAT-STA assessed at the endpoint of the experiment depicted in Fig. 3e, after intra-tumoural injection of dendritic cells. d, Per cent of GFP+CD11c+ dendritic cells (DC) present at the tumour site after injections of Flt3 ligand-derived dendritic cells from actin–GFP mice. Depicted are the percentages detected in the tumour of both genotypes injected with either wild-type or actin–GFP dendritic cells as well as in the TdLNs for the actin–GFP injected mice (n = 4). All data are mean ± s.e.m., Mann–Whitney U test. *P ≤ 0.05.
